001     127812
005     20240228140951.0
024 7 _ |a 10.1002/ijc.29298
|2 doi
024 7 _ |a pmid:25353388
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:2825760
|2 altmetric
037 _ _ |a DKFZ-2017-03834
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Wrage, Michaela
|b 0
245 _ _ |a Identification of HERC5 and its potential role in NSCLC progression.
260 _ _ |a Bognor Regis
|c 2015
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521793814_5360
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a For better lung cancer diagnosis and therapy, early detection markers of tumor dissemination are urgently needed, as most lung cancers do not show symptoms until extensive metastasis formation has already taken place. Our previous studies showed that in non-small cell lung cancer (NSCLC) early tumor dissemination is associated with a loss of chromosome 4q12-q32 and the presence of disseminated tumor cells (DTC) in the bone marrow. In order to identify the potential target gene in this region, a screen for methylation-dependent expression was performed. Lung cancer cell lines showing a loss of 4q as well as a normal bronchial epithelial cell line as control were treated with 5-aza-2'-deoxycytidine (5-aza-CdR) followed by expression profiling. Seven genes within the 4q target region, which have been associated with a positive DTC status before were found to be regulated by hypermethylation. QRT-PCR in an independent sample set identified HERC5 as a potential target gene. Quantitative methylation analysis of these lung tissue samples revealed that HERC5 promoter hypermethylation was significantly associated with positive DTC status (p = 0.020) and occurrence of brain metastases (p = 0.015). In addition, hypermethylation of the HERC5 promoter in NSCLC was identified as a predictor for poor survival for Stage I adenocarcinoma patients (p = 0.022) and also for poor overall survival in metastatic lung cancer patients (p = 0.028). In conclusion, HERC5 may function as a prognostic marker and is associated with tumor dissemination in lung cancer.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a HERC5 protein, human
|2 NLM Chemicals
650 _ 7 |a Intracellular Signaling Peptides and Proteins
|2 NLM Chemicals
650 _ 7 |a decitabine
|0 776B62CQ27
|2 NLM Chemicals
650 _ 7 |a Azacitidine
|0 M801H13NRU
|2 NLM Chemicals
700 1 _ |a Hagmann, Wolfgang
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kemming, Dirk
|b 2
700 1 _ |a Uzunoglu, Faik G
|b 3
700 1 _ |a Riethdorf, Sabine
|b 4
700 1 _ |a Effenberger, Katharina
|b 5
700 1 _ |a Westphal, Manfred
|b 6
700 1 _ |a Lamszus, Katrin
|b 7
700 1 _ |a Kim, Soo-Zin
|b 8
700 1 _ |a Becker, Natalia
|0 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0
|b 9
|u dkfz
700 1 _ |a Izbicki, Jakob R
|b 10
700 1 _ |a Sandoval, Juan
|b 11
700 1 _ |a Esteller, Manel
|b 12
700 1 _ |a Pantel, Klaus
|b 13
700 1 _ |a Risch, Angela
|0 P:(DE-He78)4981f4ef151aea881f38b33df8e35a21
|b 14
|u dkfz
700 1 _ |a Wikman, Harriet
|b 15
773 _ _ |a 10.1002/ijc.29298
|g Vol. 136, no. 10, p. 2264 - 2272
|0 PERI:(DE-600)1474822-8
|n 10
|p 2264 - 2272
|t International journal of cancer
|v 136
|y 2015
|x 0020-7136
909 C O |o oai:inrepo02.dkfz.de:127812
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)ecb33fb615e08035fdcefcaebfdff8f0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)4981f4ef151aea881f38b33df8e35a21
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2015
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)C010-20160331
|k C010
|l Epigenomik und Krebsrisikofaktoren
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)C010-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21